Literature DB >> 12354066

Dynamics and binding modes of free cdk2 and its two complexes with inhibitors studied by computer simulations.

Michal Otyepka1, Zdenek Kríz, Jaroslav Koca.   

Abstract

This article presents a molecular dynamics (MD) study of the cdk2 enzyme and its two complexes with the inhibitors isopentenyladenine and roscovitine using the Cornell et al. force field from the AMBER software package. The results show that inserting an inhibitor into the enzyme active site does not considerably change enzyme structure but it seemingly changes the distribution of internal motions. The inhibitor causes differences in the domain motions in free cdk2 and in its complexes. It was found out that repulsion of roscovitine N9 substituent causes conformational change on Lys 33 side chain. Isopentenyladenine forms with Lys 33 side chain terminal amino group a hydrogen bond. It implies that the cavity, where N9 substituent of roscovitine is buried, can adopt larger substituent due to Lys 33 side chain flexibility. The composition of electrostatic and van der Waals interactions between the inhibitor and the enzyme were also calculated along both cdk2/inhibitor MD trajectories together with MM-PB/GBSA analysis. These results show that isopentenyladenine-like inhibitors could be more effective after modifications leading to an increase in their van der Waals contact with the enzyme. We suggest that a way leading to better inhibitors occupying isopentenyladenine binding mode could be: to keep N9 and N7 purine positions free, to keep 3,3-dimethylallylamino group at C6 position, and to add, e.g., benzylamino group at C2 position. The results support the idea that the isopentenyladenine binding mode can be used for cdk2 inhibitors design and that all possibilities to improve this binding mode were not uncovered yet.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12354066     DOI: 10.1080/07391102.2002.10506830

Source DB:  PubMed          Journal:  J Biomol Struct Dyn        ISSN: 0739-1102


  8 in total

1.  Transferable scoring function based on semiempirical quantum mechanical PM6-DH2 method: CDK2 with 15 structurally diverse inhibitors.

Authors:  Petr Dobeš; Jindřich Fanfrlík; Jan Rezáč; Michal Otyepka; Pavel Hobza
Journal:  J Comput Aided Mol Des       Date:  2011-02-01       Impact factor: 3.686

2.  Study of the inhibition of cyclin-dependent kinases with roscovitine and indirubin-3'-oxime from molecular dynamics simulations.

Authors:  Bing Zhang; Vincent B C Tan; Kian Meng Lim; Tong Earn Tay; Shulin Zhuang
Journal:  J Mol Model       Date:  2006-06-13       Impact factor: 1.810

3.  Molecular dynamics simulations on the inhibition of cyclin-dependent kinases 2 and 5 in the presence of activators.

Authors:  Bing Zhang; Vincent B C Tan; Kian Meng Lim; Tong Earn Tay
Journal:  J Comput Aided Mol Des       Date:  2006-10-13       Impact factor: 3.686

4.  Study of a ligand complexed with Cdk2/Cdk4 by computer simulation.

Authors:  Yongjun Jiang; Jianwei Zou; Chunshan Gui
Journal:  J Mol Model       Date:  2005-06-01       Impact factor: 1.810

5.  The mechanism of inhibition of the cyclin-dependent kinase-2 as revealed by the molecular dynamics study on the complex CDK2 with the peptide substrate HHASPRK.

Authors:  Iveta Bártová; Michal Otyepka; Zdenek Kríz; Jaroslav Koca
Journal:  Protein Sci       Date:  2005-01-04       Impact factor: 6.725

6.  Activation and inhibition of cyclin-dependent kinase-2 by phosphorylation; a molecular dynamics study reveals the functional importance of the glycine-rich loop.

Authors:  Iveta Bártová; Michal Otyepka; Zdenek Kríz; Jaroslav Koca
Journal:  Protein Sci       Date:  2004-05-07       Impact factor: 6.725

7.  Structure-kinetic relationship study of CDK8/CycC specific compounds.

Authors:  Elisabeth V Schneider; Jark Böttcher; Robert Huber; Klaus Maskos; Lars Neumann
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-29       Impact factor: 11.205

8.  Functional flexibility of human cyclin-dependent kinase-2 and its evolutionary conservation.

Authors:  Iveta Bártová; Jaroslav Koca; Michal Otyepka
Journal:  Protein Sci       Date:  2007-11-27       Impact factor: 6.725

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.